Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting polypeptide 1B1 (OATP1B1) and cytochrome P450...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Vanessa Zhu, Jürgen Burhenne, Johanna Weiss, Mathias Haag, Ute Hofmann, Matthias Schwab, Stephan Urban, Gerd Mikus, David Czock, Walter E. Haefeli, Antje Blank
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2023-04-01
Rangatū:	Frontiers in Pharmacology
Ngā marau:	bulevirtide myrcludex B hepatitis D virus infection drug-drug interaction (DDI) SLCO1B OATP1B
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1128547/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!